Kane Biotech Inc. (KNBIF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.23 Million CAD | -17.82% |
| 2022 | -2.94 Million CAD | 35.41% |
| 2021 | -4.24 Million CAD | -16.5% |
| 2020 | -3.64 Million CAD | -6.46% |
| 2019 | -3.42 Million CAD | -10.63% |
| 2018 | -3.09 Million CAD | -18.69% |
| 2017 | -3.18 Million CAD | -3.79% |
| 2016 | -2.38 Million CAD | -49.43% |
| 2015 | -1.56 Million CAD | -14.14% |
| 2014 | -1.47 Million CAD | -9.56% |
| 2013 | -1.56 Million CAD | -5.58% |
| 2012 | -1.27 Million CAD | -9.3% |
| 2011 | -1.16 Million CAD | -37.18% |
| 2010 | -849.92 Thousand CAD | -3.99% |
| 2009 | -817.32 Thousand CAD | 14.39% |
| 2008 | -954.76 Thousand CAD | -2.74% |
| 2007 | -929.25 Thousand CAD | -11.61% |
| 2006 | -832.6 Thousand CAD | 16.38% |
| 2005 | -969.55 Thousand CAD | -69.75% |
| 2004 | -600.01 Thousand CAD | -51.53% |
| 2003 | -406.86 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.17 Million CAD | -7.32% |
| 2024 Q2 | -1.04 Million CAD | 9.85% |
| 2023 FY | - CAD | -30.57% |
| 2023 Q3 | -1.11 Million CAD | -108.38% |
| 2023 Q1 | -1.01 Million CAD | -113.02% |
| 2023 Q2 | -535.72 Thousand CAD | 47.26% |
| 2023 Q4 | -815.64 Thousand CAD | 26.94% |
| 2022 Q2 | -561.68 Thousand CAD | 40.87% |
| 2022 Q4 | -476.82 Thousand CAD | 36.98% |
| 2022 FY | - CAD | 35.41% |
| 2022 Q1 | -950 Thousand CAD | 11.23% |
| 2022 Q3 | -756.67 Thousand CAD | -34.71% |
| 2021 Q2 | -872.78 Thousand CAD | 3.55% |
| 2021 Q1 | -904.92 Thousand CAD | -9.04% |
| 2021 FY | - CAD | -16.5% |
| 2021 Q3 | -1.4 Million CAD | -60.63% |
| 2021 Q4 | -1.07 Million CAD | 23.67% |
| 2020 Q2 | -486.48 Thousand CAD | 63.56% |
| 2020 Q1 | -1.33 Million CAD | -21.71% |
| 2020 Q4 | -829.9 Thousand CAD | 16.72% |
| 2020 FY | - CAD | -6.46% |
| 2020 Q3 | -996.52 Thousand CAD | -104.84% |
| 2019 Q2 | -940.98 Thousand CAD | -55.15% |
| 2019 Q4 | -1.09 Million CAD | -40.19% |
| 2019 FY | - CAD | -10.63% |
| 2019 Q3 | -782.37 Thousand CAD | 16.86% |
| 2019 Q1 | -606.5 Thousand CAD | 4.49% |
| 2018 Q4 | -635.02 Thousand CAD | 30.01% |
| 2018 Q2 | -683.44 Thousand CAD | 21.59% |
| 2018 FY | - CAD | -18.69% |
| 2018 Q3 | -907.34 Thousand CAD | -32.76% |
| 2018 Q1 | -871.61 Thousand CAD | -424.79% |
| 2017 Q4 | -166.08 Thousand CAD | 80.55% |
| 2017 Q3 | -853.74 Thousand CAD | -18.24% |
| 2017 Q2 | -722.02 Thousand CAD | 16.8% |
| 2017 FY | - CAD | -3.79% |
| 2017 Q1 | -867.82 Thousand CAD | -87.14% |
| 2016 Q4 | -463.72 Thousand CAD | 19.92% |
| 2016 Q1 | -591.77 Thousand CAD | -34.02% |
| 2016 FY | - CAD | -49.43% |
| 2016 Q3 | -579.08 Thousand CAD | 34.18% |
| 2016 Q2 | -879.79 Thousand CAD | -48.67% |
| 2015 Q3 | -372.16 Thousand CAD | 11.26% |
| 2015 Q4 | -441.54 Thousand CAD | -18.64% |
| 2015 FY | - CAD | -14.14% |
| 2015 Q2 | -419.37 Thousand CAD | 6.72% |
| 2015 Q1 | -449.56 Thousand CAD | -8.38% |
| 2014 Q1 | -275.72 Thousand CAD | -147.2% |
| 2014 Q2 | -477.11 Thousand CAD | -73.04% |
| 2014 Q3 | -306.52 Thousand CAD | 35.75% |
| 2014 FY | - CAD | -9.56% |
| 2014 Q4 | -414.8 Thousand CAD | -35.33% |
| 2013 Q3 | -321.24 Thousand CAD | -1.53% |
| 2013 Q2 | -316.41 Thousand CAD | 51.7% |
| 2013 FY | - CAD | -5.58% |
| 2013 Q1 | -655.04 Thousand CAD | -62.87% |
| 2013 Q4 | -111.53 Thousand CAD | 65.28% |
| 2012 Q2 | -338.65 Thousand CAD | -12.14% |
| 2012 Q3 | -379.04 Thousand CAD | -11.93% |
| 2012 Q4 | -402.19 Thousand CAD | -6.11% |
| 2012 FY | - CAD | -9.3% |
| 2012 Q1 | -302 Thousand CAD | 0.64% |
| 2011 Q4 | -303.95 Thousand CAD | 9.16% |
| 2011 Q3 | -334.59 Thousand CAD | -53.15% |
| 2011 FY | - CAD | -37.18% |
| 2011 Q2 | -218.47 Thousand CAD | 37.26% |
| 2011 Q1 | -348.23 Thousand CAD | -108.85% |
| 2010 Q3 | -257.63 Thousand CAD | -45.02% |
| 2010 Q4 | -166.74 Thousand CAD | 35.28% |
| 2010 FY | - CAD | -3.99% |
| 2010 Q1 | -247.89 Thousand CAD | -162.5% |
| 2010 Q2 | -177.65 Thousand CAD | 28.34% |
| 2009 Q4 | -94.43 Thousand CAD | 68.4% |
| 2009 FY | - CAD | 14.39% |
| 2009 Q1 | -197.22 Thousand CAD | -84.5% |
| 2009 Q3 | -298.81 Thousand CAD | -31.73% |
| 2009 Q2 | -226.84 Thousand CAD | -15.02% |
| 2008 FY | - CAD | -2.74% |
| 2008 Q4 | -106.89 Thousand CAD | 70.5% |
| 2008 Q2 | -341.58 Thousand CAD | -69.09% |
| 2008 Q1 | -202 Thousand CAD | 6.45% |
| 2008 Q3 | -362.41 Thousand CAD | -6.1% |
| 2007 Q2 | -365.23 Thousand CAD | -97.12% |
| 2007 Q4 | -215.94 Thousand CAD | -33.01% |
| 2007 Q3 | -162.35 Thousand CAD | 55.55% |
| 2007 FY | - CAD | -11.61% |
| 2007 Q1 | -185.28 Thousand CAD | 28.01% |
| 2006 Q1 | -149.85 Thousand CAD | 44.44% |
| 2006 FY | - CAD | 16.38% |
| 2006 Q3 | -192.92 Thousand CAD | 17.62% |
| 2006 Q2 | -234.18 Thousand CAD | -56.27% |
| 2006 Q4 | -257.37 Thousand CAD | -33.4% |
| 2005 Q2 | -259.33 Thousand CAD | -27.76% |
| 2005 Q4 | -269.7 Thousand CAD | -5.82% |
| 2005 FY | - CAD | -69.75% |
| 2005 Q1 | -202.97 Thousand CAD | 13.06% |
| 2005 Q3 | -254.86 Thousand CAD | 1.72% |
| 2004 Q1 | -102.98 Thousand CAD | -128.81% |
| 2004 FY | - CAD | -51.53% |
| 2004 Q3 | -95.2 Thousand CAD | 34.08% |
| 2004 Q2 | -144.42 Thousand CAD | -40.24% |
| 2004 Q4 | -233.47 Thousand CAD | -145.23% |
| 2003 Q4 | -45 Thousand CAD | 73.63% |
| 2003 FY | - CAD | 0.0% |
| 2003 Q2 | -24.18 Thousand CAD | 0.0% |
| 2003 Q3 | -170.65 Thousand CAD | -605.63% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | -84.824% |
| Skye Bioscience, Inc. | -13.54 Million USD | 76.125% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.439% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 713.237% |
| Qrons Inc. | -40.08 Thousand USD | -7969.696% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 57.181% |
| CSL Limited | 4.78 Billion USD | 100.068% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 81.379% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 16.731% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -245.207% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.155% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -780.782% |
| Rebus Holdings, Inc. | -951 Thousand USD | -240.107% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -411.446% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 79.619% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.447% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 45.447% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1252.463% |
| SQZ Biotechnologies Company | -64.14 Million USD | 94.957% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -22.31% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -110.567% |
| Mesoblast Limited | -62.38 Million USD | 94.816% |
| Marizyme, Inc. | -34.28 Million USD | 90.565% |
| Genus plc | 73.7 Million USD | 104.389% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 51.079% |
| Pharming Group N.V. | 9.87 Million USD | 132.747% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -117.453% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 8.813% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 63.128% |
| ContraFect Corporation | -64.99 Million USD | 95.024% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 28.54% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -130.732% |
| IMV Inc. | -35.52 Million USD | 90.895% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -39.185% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -524.349% |
| ONE Bio Corp. | 13.61 Million USD | 123.76% |
| Accustem Sciences Inc. | -3.74 Million USD | 13.666% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 93.293% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -155.255% |
| Q BioMed Inc. | -617.62 Thousand USD | -423.683% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 190.549% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -41.582% |
| Biomind Labs Inc. | -1.03 Million USD | -212.64% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 91.84% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -11.827% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 54.835% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 48202.543% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -12837.66% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -29.275% |
| GB Sciences, Inc. | -1.41 Million USD | -127.794% |
| Alpha Cognition Inc. | -9.7 Million USD | 66.675% |
| HST Global, Inc. | -5303.00 USD | -60892.174% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -57.239% |
| Halberd Corporation | -74.27 Thousand USD | -4254.414% |
| Enzolytics Inc. | -2.12 Million USD | -52.421% |
| Agentix Corp. | -1.37 Million USD | -135.786% |
| Resverlogix Corp. | -11.74 Million USD | 72.454% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -5.596% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 98.503% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 365.77% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 136.531% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -115.785% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 953.759% |
| AVAX Technologies, Inc. | -6.11 Million USD | 47.086% |
| Zenith Capital Corp. | -8.6 Million USD | 62.417% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.7% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -18466.184% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -32.208% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1737.481% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -68.379% |
| Kadimastem Ltd | -2.62 Million USD | -23.245% |
| Helix BioMedix, Inc. | -1.04 Million USD | -209.125% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1686.101% |
| LadRx Corporation | 412.28 Thousand USD | 884.513% |
| Cell Source, Inc. | -4.27 Million USD | 24.297% |
| Regen BioPharma, Inc. | 1.46 Million USD | 320.635% |
| NovAccess Global Inc. | -1.03 Million USD | -212.565% |
| Affymax, Inc. | -14.29 Million USD | 77.374% |
| Itoco Inc. | -1.86 Million USD | -73.056% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -752.014% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -189.822% |
| Mobile Lads Corp. | -2.24 Million USD | -44.319% |
| CytoDyn Inc. | -18.02 Million USD | 82.06% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3992.694% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -26348.728% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -565.959% |
| SYBLEU INC | -141.57 Thousand USD | -2184.659% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -204.556% |
| International Stem Cell Corporation | 202 Thousand USD | 1701.196% |
| Bioxytran, Inc. | -3.82 Million USD | 15.333% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6044.405% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -31.377% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 90.983% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -7087.589% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -18.131% |
| Neutra Corp. | -181.24 Thousand USD | -1684.534% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 83.955% |
| PureTech Health plc | -11.62 Million USD | 72.182% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 83.954% |
| IXICO plc | -707 Thousand USD | -357.484% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 57.913% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 93.31% |
| CSL Limited | 4.73 Billion USD | 100.068% |
| Cellectis S.A. | -92.63 Million USD | 96.508% |